Vaxxas develops needle-free HD-MAP patches that use microprojections to deliver medicine directly to immune cells beneath the skin.
Vaxxas has raised $31.9M in total funding. The most recent round was Series D. The last funding was announced in August 2025.
Vaxxas's investors include Bill & Melinda Gates Foundation, Wellcome Trust, Brandon Capital, OneVentures, Biomedical Advanced Research and Development Authority (BARDA).
Vaxxas is headquartered in Hamilton, Australia.
Vaxxas develops needle-free HD-MAP patches that use microprojections to deliver medicine directly to immune cells beneath the skin.
Vaxxas is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vaxxas — Funding & Investors." VCBacked, August 25, 2025, https://www.vcbacked.co/company/vaxxas. Accessed September 15, 2026.
VCBacked. (2025). Vaxxas — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/vaxxas
{{cite web |title=Vaxxas — Funding & Investors |url=https://www.vcbacked.co/company/vaxxas |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated